Tan L., Lovejoy DA (2009) Neuroprotection, neuronal remodelling, and anxiety-like behaviour: The role of the teneurin and teneurin C-terminal associated peptide (TCAP) system in the hippocampus. American Journal of Neuroprotection and Neuroregeneration. 1: 3-10.
Tan L, Xu K, Vaccarino FJ, Lovejoy DA, Rotzinger S (2009) Teneurin C-terminal associated peptide (TCAP)-1 attenuates corticotropin-releasing factor (CRF)-induced c-Fos expression in the limbic system and modulates anxiety behaviour in male Wistar rats Behavioural Brain Research 201, 198-206.
Lovejoy DA, Rotzinger S, Barsyte-Lovejoy, D (2009) Evolution of complementary peptide systems: Teneurin C-terminal associated peptide (TCAP) and corticotropin-releasing factor (CRF) superfamilies. Annals of the New York Academy of Sciences. 1163, 215-220.
The information posted here was accurate at the time of posting, but may be superseded by subsequent releases.
May 25, 2011 Protagenic Therapeutics to Present at the BioFinance 2011 Conference.
January 17, 2011 Australian Patent Number 2003221575 issued for “TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND USES THEREOF”.
September 22, 2008 Protagenic Therapeutics to Present at the BioContact 2008 Symposium.
April 18 2008 Letter to Shareholders.
March 20 2008 Protagenic Therapeutics Raised Approximately $1 Million Through Private Placement.
February 19 2005 Globe and Mail
No Fear Factor? by Zoe Cormier.
A University of Toronto scientist has discovered a family of hormones that have the potential to create medications to treat anxiety disorders.